Core Insights - Gain Therapeutics, Inc. is presenting its lead drug candidate GT-02287 at the Society for Neuroscience annual meeting, focusing on its potential in treating Parkinson's disease [1][2] Company Overview - Gain Therapeutics is a clinical-stage biotechnology company specializing in the discovery and development of allosteric small molecule therapies [7] - The company is advancing GT-02287, which targets the lysosomal enzyme glucocerebrosidase (GCase) and is currently in a Phase 1b clinical trial for Parkinson's disease [7][5] Drug Candidate Details - GT-02287 is an orally administered small molecule that acts as an allosteric modulator, restoring GCase function impaired by GBA1 mutations or age-related stress [2] - Preclinical studies indicate that GT-02287 can reduce neuroinflammation, neuronal death, and restore motor function in models of both GBA1-PD and idiopathic PD [3][2] Clinical Trial Progress - A Phase 1 study showed favorable safety and tolerability, with increased GCase activity in participants receiving GT-02287 [4] - The ongoing Phase 1b trial aims to evaluate safety and tolerability over 3 months, with early observations suggesting disease-modifying effects [5] Funding and Support - Gain Therapeutics has received funding from The Michael J. Fox Foundation, The Silverstein Foundation, and the Eurostars-2 program, indicating strong support for its Parkinson's disease program [6] Research and Development Approach - The company utilizes its Magellan™ platform to discover novel allosteric small molecule modulators, targeting various disorders including neurodegenerative diseases and rare genetic disorders [8]

Core Viewpoint - Gain Therapeutics, Inc. has announced a public offering of 4,501,640 shares of common stock and warrants, aiming to raise approximately $7.0 million for the development of its lead product candidate GT-02287 and general corporate purposes [1][3][4]. Group 1: Offering Details - The public offering price is set at $3.11 for two shares of common stock and one warrant, translating to an effective price of $1.55 per share and $0.01 per warrant [1]. - The warrants will have an exercise price of $1.65 per share, are immediately exercisable, and will expire five years after issuance [1]. - The underwriter has a 30-day option to purchase up to an additional 15% of shares and/or warrants at the public offering price [2]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized for the clinical and nonclinical development of GT-02287, targeting neurodegenerative diseases such as GBA1 Parkinson's disease, as well as for general corporate purposes [4]. Group 3: Company Overview - Gain Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing next-generation allosteric therapies, with GT-02287 currently in a Phase 1b clinical trial for Parkinson's disease [7]. - The company employs its Magellan™ platform to discover novel allosteric small molecule modulators aimed at treating various difficult-to-treat disorders, including neurodegenerative diseases and rare genetic disorders [8].